Background: Parenteral nutrition (PN) is a high-alert medication available for patient care within a complex clinical process. Beyond application of best practice recommendations to guide safe use and optimize clinical outcome, several issues are better addressed through evidence-based policies, procedures, and practices. This document provides evidence-based guidance for clinical practices involving PN prescribing, order review, and preparation.
Method: A systematic review of the best available evidence was used by an expert work group to answer a series of questions about PN prescribing, order review, compounding, labeling, and dispensing. Concepts from the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) format were applied as appropriate. The specific clinical guideline recommendations were developed using consensus prior to review and approval by the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. The following questions were addressed: (1) Does education of prescribers improve PN ordering? (2) What is the maximum safe osmolarity of PN admixtures intended for peripheral vein administration? (3) What are the appropriate calcium intake and calcium-phosphate ratios in PN for optimal neonatal bone mineralization? (4) What are the clinical advantages or disadvantages of commercially available premade ("premixed") multichambered PN formulations compared with traditional/customized PN formulations? (5) What are the clinical (infection, catheter occlusion) advantages or disadvantages of 2-in-1 compared with 3-in-1 PN admixtures? (6) What macronutrient dosing limits are expected to provide for the most stable 3-in-1 admixtures? (7) What are the most appropriate recommendations for optimizing calcium (gluconate) and (Na- or K-) phosphate compatibility in PN admixtures? (8) What micronutrient contamination is present in parenteral stock solutions currently used to compound PN admixtures? (9) Is it safe to use the PN admixture as a vehicle for non-nutrient medication delivery? (10) Should heparin be included in the PN admixture to reduce the risk of central vein thrombosis? (11) What methods of repackaging intravenous fat emulsion (IVFE) into smaller patient-specific volumes are safe? (12) What beyond-use date should be used for (a) IVFE dispensed for separate infusion in the original container and (b) repackaged IVFE?
Keywords: GRADE; clinical guidelines; nutrition; parenteral formulas/compounding; parenteral nutrition.
Boullata JI, Holcombe B, Sacks G, Gervasio J, Adams SC, Christensen M, Durfee S, Ayers P, Marshall N, Guenter P; Parenteral Nutrition Safety Committee, American Society for Parenteral and Enteral Nutrition. Boullata JI, et al. Nutr Clin Pract. 2016 Aug;31(4):548-55. doi: 10.1177/0884533616653833. Epub 2016 Jun 17. Nutr Clin Pract. 2016. PMID: 27317615 Review.
MacKay M, Anderson C, Boehme S, Cash J, Zobell J. MacKay M, et al. Nutr Clin Pract. 2016 Apr;31(2):195-206. doi: 10.1177/0884533615591606. Epub 2015 Jul 24. Nutr Clin Pract. 2016. PMID: 26214511
DeLegge MH. DeLegge MH. JPEN J Parenter Enteral Nutr. 2012 Mar;36(2 Suppl):56S-61S. doi: 10.1177/0148607111435333. Epub 2012 Feb 2. JPEN J Parenter Enteral Nutr. 2012. PMID: 22301323
Kochevar M, Guenter P, Holcombe B, Malone A, Mirtallo J; ASPEN Board of Directors and Task Force on Parenteral Nutrition Standardization. Kochevar M, et al. JPEN J Parenter Enteral Nutr. 2007 Sep-Oct;31(5):441-8. doi: 10.1177/0148607107031005441. JPEN J Parenter Enteral Nutr. 2007. PMID: 17712154
Kumpf VJ, de Aguilar-Nascimento JE, Diaz-Pizarro Graf JI, Hall AM, McKeever L, Steiger E, Winkler MF, Compher CW; FELANPE; American Society for Parenteral and Enteral Nutrition. Kumpf VJ, et al. JPEN J Parenter Enteral Nutr. 2017 Jan;41(1):104-112. doi: 10.1177/0148607116680792. Epub 2016 Dec 5. JPEN J Parenter Enteral Nutr. 2017. PMID: 27913762 Review.
Al Qurashi M, Mohammad H, Aga SS, Mustafa A, Alallah J, Al Hindi M, Al Harbi M, Hasosah M. Al Qurashi M, et al. Pediatr Rep. 2024 Jun 26;16(3):551-557. doi: 10.3390/pediatric16030046. Pediatr Rep. 2024. PMID: 39051233 Free PMC article.
Otero-Millán L, Bea-Mascato B, Legido Soto JL, Martínez-López-De-Castro N, Lago-Rivero N. Otero-Millán L, et al. Pharmaceutics. 2024 Apr 23;16(5):572. doi: 10.3390/pharmaceutics16050572. Pharmaceutics. 2024. PMID: 38794234 Free PMC article.
Amir M, Danish A, Channa S. Amir M, et al. BMJ Open Qual. 2024 May 7;13(Suppl 2):e002382. doi: 10.1136/bmjoq-2023-002382. BMJ Open Qual. 2024. PMID: 38719523 Free PMC article.
Otero-Millán L, Bea-Mascato B, Legido Soto JL, Martínez-López-De-Castro N, Lago-Rivero N. Otero-Millán L, et al. Pharmaceutics. 2024 Feb 23;16(3):316. doi: 10.3390/pharmaceutics16030316. Pharmaceutics. 2024. PMID: 38543210 Free PMC article.
Usuda H, Ikeda H, Watanabe S, Sato S, Fee EL, Carter SWD, Kumagai Y, Saito Y, Takahashi T, Takahashi Y, Kawamura S, Hanita T, Saito M, Kikuchi A, Choolani MA, Yaegashi N, Kemp MW. Usuda H, et al. Front Physiol. 2023 Aug 24;14:1219185. doi: 10.3389/fphys.2023.1219185. eCollection 2023. Front Physiol. 2023. PMID: 37692998 Free PMC article.